好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Higher Circulating Levels of Short-chain Fatty Acids are Associated with Good Neurologic Outcome After Cardiac Arrest: A Pilot Study
Neuro Trauma and Critical Care
S17 - Neurocritical Care (2:24 PM-2:36 PM)
008

Nearly 300,000 Americans suffer cardiac arrest annually. Many die or are severely impaired by neurologic injury, which is worsened by the inflammatory response that develops after reperfusion. In both neurodegenerative diseases and acute brain injury, neuropathology is modified by the composition of the gut microbiome via impaired production of short-chain fatty acids (SCFAs). SCFAs reduce inflammatory cytokine release and constrain the immune response. Whether the composition of the gut microbiome or its metabolites affects neurologic outcome after cardiac arrest (CA) remains unknown.

To determine the relationship between circulating microbial metabolites and neurologic outcome after cardiac arrest (CA).

We performed a single-center, prospective cohort study of comatose CA survivors (n=26) at an urban trauma center. Plasma samples were collected 24 hours after intensive care unit (ICU) admission and gas chromatography-mass spectrometry was used to measure SCFAs. Neurologic outcome was measured with the Cerebral Performance Category (CPC), which was determined at 3 months by a blinded evaluator. Cytotoxic brain edema was analyzed using the Cortex Score from diffusion-weight magnetic resonance imaging (MRI).

The average age was 62 years and time to return of spontaneous circulation (ROSC) was 21.5 minutes. Subjects were predominantly male and had a non-shockable rhythm. In subjects with a good outcome at discharge (CPC 1-2; n=8), plasma levels of SCFAs were significantly higher than in subjects with a poor outcome (CPC 3-5, n=18; all p<0.05). Higher SCFA levels were associated with a reduced cytotoxic brain edema 3-5 days after CA. Higher circulating SCFA level was significantly associated with a good neurologic outcome after adjusting for the MIRACLE-2 score, a validated outcome prediction score in CA (aOR 11.3; 1.2-107.0).

Together, these results suggest that higher circulating SCFAs after CA are independently associated with neurologic outcome after CA and highlight their prognostic and therapeutic potential in this vulnerable population.

Authors/Disclosures
Ori Lieberman, MD, PhD (UCSF)
PRESENTER
Dr. Lieberman has received research support from UCSF.
Virginia Yao Miss Yao has nothing to disclose.
Gerardo H. Velasquez Mr. Velasquez has nothing to disclose.
Sergio Baranzini (UCSF) Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Sergio Baranzini has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono . Sergio Baranzini has stock in MATE Bioservices. The institution of Sergio Baranzini has received research support from Valhalla Charitable Fund. The institution of Sergio Baranzini has received research support from Salah Foundation. The institution of Sergio Baranzini has received research support from NIH. The institution of Sergio Baranzini has received research support from NSF. Sergio Baranzini has received intellectual property interests from a discovery or technology relating to health care. Sergio Baranzini has a non-compensated relationship as a co-funder with Mate Bioservices that is relevant to AAN interests or activities.
Claude Hemphill III, MD, FAAN (Zuckerberg San Francisco General Hospital) Dr. Hemphill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Hemphill has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for various legal firms. The institution of Dr. Hemphill has received research support from NIH/NINDS.
Neel Singhal, MD, PhD (UCSF) Dr. Singhal has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. The institution of Dr. Singhal has received research support from VA Office of Sponsored Research. The institution of Dr. Singhal has received research support from Bayer.
Edilberto Amorim, MD The institution of Dr. Amorim has received research support from American Heart Association. The institution of Dr. Amorim has received research support from Society of Critical Care Medicine. The institution of Dr. Amorim has received research support from Zoll Foundation. The institution of Dr. Amorim has received research support from Hellman Foundation. The institution of Dr. Amorim has received research support from Regents of the University of California. The institution of Dr. Amorim has received research support from Citizens United Against Epilepsy. The institution of Dr. Amorim has received research support from Regents of the University of California. The institution of Dr. Amorim has received research support from American Heart Association. The institution of Dr. Amorim has received research support from NIH. The institution of Dr. Amorim has received research support from Department of Defense.